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Abstract
Background: Glioblastoma multiforme (GBM) is the most malignant intracranial tumour that develops in both
adults and children. Microarray gene analyses have confirmed that the human YKL-40 gene is one of the most
over-expressed genes in these tumours but not in normal brain tissue. Clinical studies have shown that serum
YKL-40 levels are positively correlated with tumour burden in addition to being an independent prognostic factor
of a short relapse-free interval as well as short overall survival in patients with various cancers. Our previous study
revealed that YKL-40 was closely correlated with the pathological grades of human primary astrocytomas and
played a crucial role in glioma cell proliferation. Hence, YKL-40 could be an attractive target in the design of anti-
cancer therapies.
Methods: Cell viability and invasion assays were performed to detect the cell proliferation and invasive ability of
U87 cells induced by resveratrol (3, 5, 4’-trihydroxystilbene; Res) or YKL-40 small-interfering RNAs (siRNAs). In
addition, the luciferase assay, real-time RT-PCR, western blotting, and ELISA were used to measure YKL-40 promoter
activity, mRNA, and protein expression, respectively. The expressions of phosphor-ERK1/2 and ERK1/2 were
determined by western blotting.
Results: Res inhibited U87 cell proliferation and invasion in vitro and repressed YKL-40 in U87 cells by decreasing
the activity of its promoter and reducing mRNA transcription and protein expression in vitro. YKL-40 siRNA
treatment also impaired the invasiveness of U87 cells. When U87 cells were cultured with 20 μM PD98059 (an
ERK1/2 inhibitor) alone, with 20 μM PD98059 and 100 μM Res, or with 100 μM Res alone for 48 h, YKL-40 protein
expression decreased most significantly in the Res-treated group. PD98059 partially reversed the decrease of YKL-40
protein expression induced by Res. Furthermore, phosphor-ERK1/2 expression was reduced by Res treatment in a
time-dependent manner.
Conclusions: We demonstrated for the first time that Res represses YKL-40 expression in vitro; in addition, the
ERK1/2 pathway is involved in this repression. This finding could extend the prospective use of Res in glioma
research and enlarge the armamentarium for treating gliomas.
Background
Malignant gliomas are the most common type of pri-
mary malignant brain tumours and are almost always
lethal in both adults and children despite the existence
of therapies, which include surgery, radiotherapy, and
chemotherapy. Patients with GBM have an average sur-
vival time of 12 to 18 months from initial diagnosis and
6 to 9 months after recurrence [1,2].
In recent years, literature reviews of patients with var-
ious types of cancer (breast, colorectal, ovarian, kidney,
prostate, small-cell lung, melanoma, and glioma) suggest
that the serum YKL-40 level detected with the enzyme-
linked immunosorbent assay (ELISA) could be a promis-
ing predictor of tumour burden and an independent
prognostic variable of a short relapse-free interval as
well as short overall survival [3-12]. More importantly,
an elevated plasma YKL-40 level could predict an
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any medium, provided the original work is properly cited.increased risk of gastrointestinal cancer after diagnosis
of any other cancer [13].
Over a decade ago, YKL-40 was identified in vitro as a
secreted glycoprotein in the culture medium of the
human osteosarcoma cell line MG63 [14]. It contains an
open reading frame of 383 amino acids and has a mole-
cular weight of 40,476 kDa [15]. The gene encoding
YKL-40 is located on chromosome 1q31-q32. The Sp1-
family transcription factors predominantly regulate
YKL-40 promoter activity during human macrophage
differentiation [16]. Although the biological function of
YKL-40 in cancer remains largely unclear, studies have
s u g g e s t e dt h a tY K L - 4 0m a yp l a yap o s i t i v er o l ei nc a n -
cer cell survival and differentiation, protection against
apoptosis, angiogenesis stimulation, and regulation of
extracellular tissue remodeling [17-19]. Regarding glio-
mas, microarray gene analyses have revealed that the
human YKL-40 gene is one of the most over-expressed
genes in GBM, but it is not expressed in normal brain
tissue [10,20]. Furthermore, our previous study indicated
that silencing the YKL-40 gene could significantly
attenuate glioma cell proliferation by arresting the cell
cycle in the G1 phase [21]. Therefore, YKL-40 is an
attractive target in the design of anti-cancer therapies.
However, to date, there is no documentation on target-
ing YKL-40 expression for development of a novel adju-
vant glioma therapy.
In 2007, we reported that a polyphenolic natural pro-
duct, resveratrol (Res), inhibited cell growth and induced
apoptosis of C6 glioma cells in rats but not in normal
3T3 fibroblast cells [22]. In in vivo studies, Res slowed
the growth of subcutaneous gliomas in rats [23], pro-
longed survival time, and increased the survival rate in a
rat glioma model [24]. Thus, Res has significant poten-
tial clinical applications in the treatment of gliomas. On
the basis of existing literature reports and our previous
studies, we hypothesize that Res might repress YKL-40
expression, and the findings of the present study have
confirmed this to be the case. To the best of our knowl-
edge, this is the first report indicating that Res could be
a potential candidate targeting YKL-40 expression.
Methods
Cell lines and culture
A human glioblastoma cell line, U87, was purchased
from the American Type Culture Collection (ATCC;
Manassas, VA, USA). The tumour cell line was main-
tained in minimum essential medium (MEM) (Gibco
Life Science, Gaithersburg, MD, USA) supplemented
with 10% fetal bovine serum (Gibco Life Science), 2 mM
L-glutamine, 100 units/ml penicillin, and 100 μg/ml
streptomycin. All cells were cultured at 37°C in a 5%
CO2 incubator.
Cell viability assay
Cell proliferation was determined by using a WST-1 cell
proliferation reagent (Roche Applied Science, Mannheim,
Germany). In brief, 2 × 10
4 cells were seeded in a flat-
bottomed 96-well plate (Nunc, Roskilde, Denmark) and
cultured for 24 h to reach 60% to 70% confluence prior
to Res treatment. Res (Sigma, St Louis, MO, USA) was
dissolved in dimethylsulfoxide (DMSO; Wako, Osaka,
Japan) to a stock concentration of 1 mM and subse-
quently diluted with culture medium to final concentra-
tions of 0, 1, 10, and 100 μM just before use. The
concentration of DMSO in the vehicle was 1:1000. The
cells were exposed to the indicated concentrations of Res
for 0, 24, 48, and 72 h. Each group was set in 8 wells. At
each time point, 10 μl / w e l lW S T - 1r e a g e n tc u l t u r e da t
37°C for 4 h was added. The optical density was mea-
sured at 460 nm. The cell growth curves were drawn
according to the optical density of each group of cells.
The trypan blue dye cell exclusion assay was used to
determine cell viability by treating the cells with different
dosages of Res for 48 h. Cell viability is described as a
percentage of the DMSO control group, which was set as
100%. All experiments were performed in triplicate.
Cell transfection and the siRNA method
Cells were seeded at a concentration of 2.5-5 × 10
4
cells/ml and cultured for 24 h in 6-well plates in order
to reach 60% to 70% confluence before transfection. The
cells were then transfected with 20 nM SMART pool®
Reagents YKL-40 or non-targeting (random) siRNA
(Dharmacon, Lafayette, CO, USA) in the presence of
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. In brief,
lipofectamine (Invitrogen) and YKL-40 siRNA or nega-
tive control siRNA were dissolved separately in antibio-
tic- and serum-free MEM. After 10 min of equilibration
at room temperature, each RNA solution was combined
with the respective volume of lipofectamine solution,
mixed gently, and allowed to form siRNA liposomes for
20-30 min at room temperature. After the cells were
washed 3 times with PBS, the 200 μl/well siRNA lipo-
some mixture was added followed by the addition of
800 μl/well antibiotic- and serum-free MEM. The cells
were incubated for 4 h, and the media were subse-
quently changed to antibiotic- and serum-containing
MEM.
Cell invasion assay
The cell invasion assay was carried out using modified
Boyden chambers consisting of transwell-precoated
matrigel membrane filter inserts with 8-μm pores in 24-
well tissue culture plates (BD Biosciences, San Diego,
CA, USA). U87 cells were pretreated with 100 μMR e s
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and plated at 5 × 10
4 cells/well in the upper transwell
chambers of inserts precoated with matrigel in serum-
and growth-factor-free medium. The bottoms of the
chambers were filled with 500 μl medium containing
10% FBS. After 24 or 48 h, matrigel-precoated inserts
were fixed and stained with Diff-Quick Fixative Solu-
tions (Dade Behring, Newark, DE, USA). Attached cells
were imaged with an Olympus digital camera mounted
to a light microscope and quantified using ImageJ soft-
ware http://rsb.info.nih.gov/ij/. Invasion was calculated
as the ratio of the number of invading cells to the total
number of cells in both sides of the membrane. Cells
were counted in triplicate membranes.
Transfection of U87 cells and luciferase reporter gene
assay
The YKL-40 promoter was cloned with PCR from
human genomic DNA using the following oligonucleo-
tides: sense 5’-TAT CTG GTA CCG TGC AGG AGT
GGG AGG AAG G-3’ and anti-sense 5’-GAT CTA
AGC TTC ATT CTG GCT GCA GCA GAG C-3’.T h e
sequences were obtained from the published human
YKL-40 promoter sequence [15]. The resultant 380-bp
fragment was inserted into the KpnIa n dHindIII sites
of the PGV-B2-basic luciferase reporter vector
(ToyoInk, Tokyo, Japan), which contains the human
YKL-40 gene sequences spanning the region between
-377 and 2 bp. Purified reporter plasmids were then
transfected into U87 cells via the lipofectamine (Invi-
trogen, Carlsbad, CA, USA) transfection method.
Reporter plasmid-transfected U87 cells were subse-
quently treated with 100 μM Res for 48 h. All assays
were corrected for total amounts of protein per reac-
tion. Transfected cells were harvested in an aliquot of
the cytoplasmic fraction. For the luciferase assay, 40 μl
aliquots were taken and the assay was carried out
according to the manufacturer’s instructions (ToyoInk).
Real-time quantitative reverse transcript-polymerase
chain reaction
Total RNA was extracted with Isogen (Nippon Gene,
Toyama, Japan), according to the manufacturer’s
instructions. cDNA was generated with the First-strand
cDNA Synthesis Kit (Amersham Biosciences, Piscataway,
NJ, USA), according to the manufacturer’s instructions.
Total RNA (1 μg) was used for each reaction with polyT
primers. Quantitative real-time PCR was performed
using an ABI Prism 7000 (Applied Biosystems, Foster
City, CA, USA) with ABI SYBR Green PCR Master Mix
(Applied Biosystems), human GADPH as an internal
control, and primers for YKL-40 (sense 5’-CCT GCT
CAG CGC AGC ACT GT-3’ and antisense 5’-GCT
TTT GAC GCT TTC CTG GTC-3’).
ELISA for YKL-40 in the culture medium
The amount of YKL-40 protein secreted by the cells was
measured in the collected medium samples with a two-
site sandwich-type ELISA (Quidel Corporation, San
Diego, CA, USA) according to the manufacturer’s
instructions. Protein concentrations were determined as
the absorbance measured using the Bio-Rad Benchmark
Microplate Reader. No detectable YKL-40 was found in
MEM containing 10% FBS. Each time point test was
analyzed in triplicate.
Western blotting
U87 cells were treated with Res (100 μM) and 20 μM
PD98059 (Calbiochem, San Diego, CA, USA) for 48 h.
DMSO (1:1000)-containing media served as vehicle.
Western blotting was then performed as described
previously [22] with primary antibodies against YKL-40
( R&DS y s t e m s ,M i n n e a p o l i s ,M N ,U S A ) ,- a c t i n ,P h o s -
pho-ERK1/2, and ERK1/2 (Cell Signaling Technology,
Beverly, MA, USA), followed by incubation for 1 h at
room temperature with a secondary antibody (HRP-
conjugated anti-rat or anti-rabbit IgG; Cell Signaling
Technology). Immunoreactive bands were visualized
using enhanced chemiluminescence (Amersham Pharma-
cia Biotech, Buckinghamshire, UK) and quantified with
LAS-1000 plus (Fujifilm, Tokyo, Japan).
Statistical analysis
All statistical analyses were performed with the Statisti-
cal Package for the Social Sciences (SPSS) 13.0 (SPSS
inc., Chicago, IL). Statistical significance between more
than 2 groups was determined using one-way ANOVA;
statistical significance between 2 groups was determined
using Student’s t-test. The significance level of all tests
was set at P < 0.05
Results
Res-induced inhibition of cellular proliferation in U87
glioblastoma cells
Aggressive tumour cell proliferation is one of the most
pronounced characteristics during the initiation and
progression of gliomas. Because of Res’ potent cancer
chemopreventive effect in carcinogenesis, we first per-
formed cell viability assays with WST-1 reagent. U87
cells were treated with increasing concentrations of Res
(DMSO; 0, 1, 10, and 100 μM, and 1 mM) for different
exposure times (0, 24, 48, and 72 h) (Figure 1A). In gen-
eral, the proliferation of U87 cells was inhibited by Res
in both a dose- and time-dependent manner. However,
1 mM Res was the maximum dosage for U87 cells.
After being treated with 1 mM Res for 24 h, U87 cells
exhibited the distinct features of cell death under the
light microscope (data not shown). Interestingly, at 72 h,
1 μM Res treatment significantly (P <0 . 0 1 )i n h i b i t e d
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treated with 100 μM Res for 48 and 72 h exhibited the
most statistically significant differences compared with
those of the other groups (P < 0.01) although there was
no significant difference between the 2 groups them-
selves (P > 0.05). At 48 h, cell viability was further rein-
forced by the trypan blue dye exclusion assay (Figure
1B). Cell morphological changes are shown in Figure
1C. Therefore, we chose 100 μM Res for 48 h as the cri-
tical point for further study.
Res-induced decrease of U87 cell invasiveness
It is well known that the highly invasive characteristics
of malignant glioma cells account for the resultant poor
therapeutic effects of radical excision. We assessed
whether the invasiveness glioma cells can be inhibited
by Res. U87 cells were pretreated with 100 μMR e so r
20 nM YKL-40 siRNA for 48 h. The same number of
cells was seeded, and the invasiveness of the U87 cells
was then determined in a modified Boyden chamber
with a matrigel-precoated membrane filter insert. After
Figure 1 U87 cell proliferation assay. A. The WST-1 assay was performed to measure U87 cell viability after treatment with increasing
concentrations of Res (DEMSO, 0, 1, 10, and 100 μM, and 1 mM) for different exposure times (0, 24, 48, or 72 h). The groups treated with 100
μM Res for 48 and 72 h showed the greatest significant difference compared with the other groups (P < 0.01). Asterisks indicate statistically
significant changes (P < 0.01) after Res treatment. Bars indicate SE. B. The trypan blue dye exclusion assay revealed the U87 cell viability after
treatment with increasing concentrations of Res (0, 1, 10, and 100 μM, and 1 mM) for 48 h. Asterisks indicate statistically significant changes (P <
0.01) after Res treatment. Bars indicate SE. C. Morphology of U87 cells treated by 100 μM Res for 48 h under a light microscope (a.b);
Morphology of U87 cells treated by 100 μM Res for 48 h in trypan blue dye cell exclusion assay (c.d). Original magnification: 40×.
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Page 4 of 9Figure 2 Matrigel invasion assay of U87 cells pretreated with 100 μM Res and siRNA YKL-40 for 48 h. A. A modified Boyden chamber
with a matrigel-precoated membrane filter insert was used to measure in vitro invasiveness. After 24 or 48 h of incubation, cells that invaded
through the membrane were stained and representative fields were photographed. Original magnification: 200 ×. B. Invasion was calculated as
the ratio of the number of invading cells to total cell numbers in both sides of the membrane. The ratio of invading cells was significantly
reduced by Res treatment. Asterisks indicate statistically significant changes (P < 0.01) after Res treatment. Columns represent the average
number of invading cells per field of at least 5 fields from 3 independent experiments. Bars indicate SE.
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decreased significantly (P < 0.01) (Figure 2) in both Res-
and siRNA-pretreated U87 cells.
Res-induced repression of YKL-40 promoter activity,
mRNA transcription, and protein expression
In our previous study, the silencing of YKL-40 inhibited
the proliferation of U87 cells [21]. In conjunction with
the cellular proliferation and invasion induced by Res
in vitro, we further speculated that Res could decrease
the expression of YKL-40. To test this hypothesis, YKL-
40 promoter was synthesized, and the luciferase assay
was conducted. Real-time RT-PCR, western blotting, and
ELISA were used to evaluate the mRNA transcription
and protein expression levels. After treatment with
100 μM Res for 48 h, YKL-40 promoter activity was sig-
nificantly reduced compared with that of the control
group (P < 0.01) (Figure 3A). YKL-40 mRNA transcrip-
tion and protein expression levels were consistently and
steadily repressed in a time-dependent manner (Figure
3B-D). Thus, Res repressed YKL-40 in U87 cells by
decreasing the activity of its promoter, mRNA transcrip-
tion, and protein expression levels in vitro.
Involvement of the ERK1/2 pathway in the Res-induced
repression of YKL-40 expression
Extracellular regulated kinase 1/2 (ERK1/2) is well
k n o w nf o ri t sc r i t i c a lr o l ei nc e l lp r o l i f e r a t i o n .I nt h i s
study, we hypothesized that the ERK1/2 pathway is
involved in the down-regulation of YKL-40 expression
by Res. In order to demonstrate this, the specific inhibi-
tor of the ERK1/2 pathway, PD98059 (20 μM), was
added along with 100 μM Res to the U87 cell culture
for 48 h. The band densities of western blotting revealed
that YKL-40 protein expression decreased most signifi-
cantly in the Res-treated group (P < 0.01); in addition,
PD98059 partially blocked the expression of YKL-40
(Figure 4A). Moreover, phosphor-ERK1/2 expression
was reduced by Res treatment in a time-dependent
manner (Figure 4B).
Discussion
The prominent hallmarks of gliomas are their character-
istics of malignant proliferation and aggressive invasion.
In a pioneering study, Nigro and colleagues determined
that immortalized human astrocytes stably transfected
with YKL-40 exhibited changes in gene expression simi-
lar to those observed in human tumours and confer
radioresistance and an increased invasive capacity
in vitro [17]. Our previous study showed that the YKL-
40 expression level was well correlated to the pathologi-
cal grade of human primary astrocytomas and acted as a
proliferation and anti-apoptosis factor in astrocytoma
cells [21]. These findings suggest that YKL-40 is a
positive regulator in the proliferation and invasiveness
of glioma cells. In the present study, we again deter-
mined that the invasion ability of U87 cells is sharply
impaired after YKL-40 gene silencing. The numerous lit-
erary reviews and our accumulated findings suggest that
YKL-40 is an attractive target for selective anticancer
drug development. Our study reveals for the first time
that a drug - Res - repressed the expression of YKL-40
Figure 3 Res repressed YKL-40 promoter activity, mRNA
transcription, and protein expression. A. Luciferase assay after
YKL-40 promoter reporter plasmid-transfected U87 cells after
treatment with 100 μM Res for 48 h. B. YKL-40 mRNA transcription
level measured using real-time RT-PCR after treatment with 100 μM
Res for 24, 48, and 72 h. C. YKL-40 protein expression levels
measured using western blotting after treatment with 100 μM Res
for 24, 48, and 72 h. D. Secreted YKL-40 protein levels in media
measured using ELISA after treatment with 100 μM Res for 24, 48,
or 72 h. Asterisks indicate statistically significant changes (P < 0.01).
Bars indicate SE.
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and protein expression levels in U87 cells in vitro.
It is widely known that Res is synthesized by a wide
range of plant species, including grapes, peanuts, pines,
and more than 70 other species in response to injury,
ultraviolet irradiation, or fungal attack. In particular, Res is
abundant in the skin of red grapes and may account for
the “French Paradox” [25]. Due to its various beneficial
health effects, such as its anti-oxidant, anti-inflammatory,
and cardioprotective activities, Res is considered as a
“state-of-the-art” medicine derived from natural sources
[26-28]. However, it was not until 1997 when Jang and
colleagues [25] published a seminal article demonstrating
the anti-carcinogenic effectso fR e sd i dt h i sp h y t o a l e x i n
attract considerable attention from oncologists as a novel
chemopreventive agent. Shortly after, tremendous progress
was made in revealing the potential role of Res in the anti-
carcinogenic process. Over the past decades, numerous
preclinical findings indicate that Res inhibits the prolifera-
tion and induces apoptosis of various cancer cells cultured
in vitro in addition to retarding the growth of implanted
tumours in vivo [22-28]; this suggests the existence of
an inverse relationship between Res and its striking inhibi-
tion associated with tumour initiation, promotion, and
progression. Recent studies have also revealed that the
chemopreventive effect of Res is significantly stronger
than that of cisplatin (CP); furthermore, co-administration
of Res (20 mg/kg) markedly enhances the chemopreven-
tion of CP in the Ehrlich ascites carcinoma (EAC) solid
tumour model [29]. Our current study further confirms
that Res inhibits the proliferation of U87 cells in both a
dose- and time-dependent manner. More interestingly, we
demonstrated that Res significantly decreased the ability of
U87 cells to invade in vitro. Thus, Res has promising roles
in natural cancer prevention and treatment [30].
As the most distinct member of the mitogen-activated
protein kinase (MAPK) family, the ERK pathway is
synonymous with cell proliferation. YKL-40 expression
is positively associated with the expression of phosphor-
ERK1/2, which is strongly correlated with poor response
to radiotherapy and negative outcomes [31]. In addition,
phosphor-ERK1/2 expression is notably decreased in
U87 cells in which YKL-40 is silenced [21]. Therefore,
we speculate that the ERK1/2 pathway is involved in
the down-regulation of YKL-40 induced by Res. The
ERK1/2-specific inhibitor, PD98059 (20 μM), was added
along with 100 μM Res to the culture medium and the
U87 cells were cultured for 48 h. As expected, YKL-40
expression decreased most significantly in the Res-trea-
ted group and partially decreased in PD98059-treated
group. This indicates that the ERK1/2 pathway is
involved in Res repressed YKL-40 expression in U87
cells. Moreover, the functional impact of Res on MAPK
signaling may depend, to some extent, on the concen-
trations of Res used under different conditions and on
the biological systems involved. Relatively low concen-
trations of Res (1 pM to 10 μM) are reported to induce
phosphor-ERK1/2 in human neuroblastoma cells,
whereas higher concentrations (50 to 100 μM) nega-
tively interfere with MAPK phosphorylation [32]. In
human coronary smooth muscle cells (HCSMC), pre-
treatment with Res (1-100 μM) triggered marked inhibi-
tion of endothelin-1-evoked cell proliferation and
ERK1/2 activation [33]. In the present study, we consis-
tently used 100 μM Res and observed significantly
decreased phosphor-ERK1/2 activity in a time-depen-
dent manner.
Conclusion
Our study demonstrates for the first time that Res
represses YKL-40 expression by decreasing its promoter
activity, mRNA transcription, and protein expression
levels in U87 cells in vitro;i na d d i t i o n ,t h eE R K 1 / 2
pathway is involved in this process. This finding sup-
ports the idea of targeting YKL-40 as a novel adjuvant
therapy in glioma treatment and expands the prospec-
t i v eu s eo fR e si na n t i - g l i o m ar e s e a r c h .W eh o p et h a t
any drug that specifically inhibits the expression of
YKL-40 might enhance the effects of tumour excision of
and improve the prognosis for glioma patients.
Figure 4 ERK1/2 pathway involvement in the Res-induced
repression of YKL-40 expression. A. YKL-40 protein expression
after treatment with 20 nM PD98059 alone, 20 nM PD98059 along
with 100 μM Res, or with 100 μM Res alone for 48 h by western
blotting. B. Phospho-ERK1/2 expression after treatment with 100 μM
Res for 24, 48, and 72 h determined by western blotting. Asterisks
indicate statistically significant changes (P < 0.01). Bars indicate SE.
Zhang et al. BMC Cancer 2010, 10:593
http://www.biomedcentral.com/1471-2407/10/593
Page 7 of 9Abbreviations
MAPK: mitogen-activated protein kinase; ERK1/2: extracellular regulated
kinase 1/2; Res: resveratrol; ELISA: enzyme linked immunosorbent assay;
MEM: minimum essential medium; siRNA: short interference RNA
Acknowledgements
This study was supported by a grant from the Foundation of Japan Ministry
of Education, Science, Sports, Culture, and Technology (No. 22390277),
Kagawa University Characteristic Prior Research Fund 2009, and the National
Natural Science Foundation of China (No. 30870843). We thank our emeritus
Prof. Seigo Nagao for his great spiritual inspiration. We thank Prof. You-hui
Zhang for his help in revising the manuscript. We thank Ms. Sachiyo Ishihara,
Ms. Tomiyo Kashihara, Ms. Naoko Iwasaki, and Ms. Ayumi Kawasaki for
preparing the materials. We also thank Ms. Julie Yamamoto for editorial
assistance.
Author details
1Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical
University, 127 West Changle Road, Xi’an, Shaanxi Province, 710032, People’s
Republic of China.
2Department of Neurological Surgery, Faculty of Medicine,
Kagawa University, 1750-1 Ikenobe, Miki-cho, Kida-gun, Kagawa 761-0793,
Japan.
3Division of Endocrinology and Metabolism, Department of Internal
Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho,
Kida-gun, Kagawa 761-0793, Japan.
4Department of Pharmacology, Faculty of
Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kida-gun, Kagawa
761-0793, Japan.
Authors’ contributions
WZ, KMu, and XZ designed and performed the study. KMa synthesized the
YKL-40 promoter. SD performed real-time RT-PCR. MO, KMi, and NK were
responsible for protein analysis. ZF and TT were responsible for the
preparation of the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 March 2010 Accepted: 28 October 2010
Published: 28 October 2010
References
1. Tamiya T, Takao S, Ichikawa T, Chayama K, Date I: Successful
chemotherapy for congenital malignant gliomas: a report of two cases.
Pediatr Neurosurg 2006, 42:240-244.
2. Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T: Proton
magnetic resonance spectroscopy reflects cellular proliferative activity in
astrocytomas. Neuroradiology 2000, 42:333-338.
3. Jensen BV, Johansen JS, Price PA: High levels of serum HER-2/neu and
YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Clin Cancer Res 2003, 9:4423-4434.
4. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ:
Serum YKL-40 and colorectal cancer. Br J Cancer 1999, 79:1494-1499.
5. Johansen JS, Drivsholm L, Price PA, Christensen IJ: High serum YKL-40 level
in patients with small cell lung cancer is related to early death. Lung
Cancer 2004, 46:333-340.
6. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA,
Iversen P: Prognostic value of PINP, bone alkaline phosphatase, CTX-I,
and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006,
66:503-513.
7. Høgdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J,
Bock JE, Glud E, Høgdall CK: High plasma YKL-40 level in patients with
ovarian cancer stage III is related to shorter survival. Oncol Rep 2003,
10:1535-1538.
8. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H:
Elevated serum level of YKL-40 is an independent prognostic factor for
poor survival in patients with metastatic melanoma. Cancer 2006,
106:1130-1139.
9. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K,
Larsen J, von der Maase H: Serum YKL-40 predicts relapse-free and
overall survival in patients with American Joint Committee on Cancer
stage I and II melanoma. J Clin Oncol 2006, 24:798-804.
10. Tanwar MK, Gilbert MR, Holland EC: Gene expression microarray analysis
reveals YKL-40 to be a potential serum marker for malignant character
in human glioma. Cancer Res 2002, 62:4364-4368.
11. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK,
Rao JS, Fleisher M, DeAngelis LM, Holland EC: YKL-40 and matrix
metalloproteinase-9 as potential serum biomarkers for patients with
high-grade gliomas. Clin Cancer Res 2006, 12:5698-5704.
12. Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL,
Bentzen J, Price PA, Andersen E: High serum levels of YKL-40 in patients
with squamous cell carcinoma of the head and neck are associated with
short survival. Int J Cancer 2008, 122:857-863.
13. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA,
Nordestgaard BG: Elevated plasma YKL-40 predicts increased risk of
gastrointestinal cancer and decreased survival after any cancer
diagnosis in the general population. J Clin Oncol 2009, 27:572-578.
14. Johansen JS, Williamson MK, Rice JS, Price PA: Identification of proteins
secreted by human osteoblastic cells in culture. J Bone Miner Res 1992,
7:501-512.
15. Hakala BE, White C, Recklies AD: Human cartilage gp-39, a major secretory
product of articular chondrocytes and synovial cells, is a mammalian
member of a chitinase protein family. J Biol Chem 1993, 268:25803-25810.
16. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R,
Krause SW: Transcriptional regulation of CHI3L1, a marker gene for late
stages of macrophage differentiation. J Biol Chem 2003, 278:44058-44067.
17. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N,
Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, Aldape KD: Integrated
array-comparative genomic hybridization and expression array profiles
identify clinically relevant molecular subtypes of glioblastoma. Cancer
Res 2005, 65:1678-1686.
18. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-
Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, et al: YKL-40, a marker
of simian immunodeficiency virus encephalitis, modulates the biological
activity of basic fibroblast growth factor. Am J Pathol 2008, 173:130-143.
19. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B,
Yan WY: KL-40, a secreted glycoprotein, promotes tumor angiogenesis.
Oncogene 2009, 28:4456-4468.
20. Shostak K, Labunskyy V, Dmitrenko V, Malisheva T, Shamayev M,
Rozumenko V, Zozulya Y, Zehetner G, Kavsan V: HC gp-39 gene is
upregulated in glioblastomas. Cancer Lett 2003, 198:203-210.
21. Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Nagao S,
Nishiyama A, Fei Z, Zhang X, Tamiya T: Association between YKL-40 and
adult primary astrocytoma. Cancer 2010, 116:2688-2697.
22. Zhang W, Fei Z, Zhen H, Zhang J, Zhang X: Resveratrol inhibits cell
growth and induces apoptosis of rat C6 glioma cells. J Neurooncol 2007,
81:231-240.
23. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK, Lin PY, Chen Y:
Resveratrol suppresses the angiogenesis and tumour growth of gliomas
in rats. Clin Cancer Res 2004, 10:2190-2202.
24. Renaud S, de Lorgeril M: Wine, alcohol, platelets, and the French paradox
for coronary heart disease. Lancet 1992, 339:1523-1526.
25. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH,
Farnsworth NR, Kinghorn AD, Mehta RG, et al: Cancer chemopreventive
activity of resveratrol, a natural product derived from grapes. Science
1997, 275:21-220.
26. Uenobe S, Nakamura S, Miyazawa M: Antimutagenic effect of resveratrol
against Trp-P-1. Mutation Res 1997, 373:197-200.
27. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: The in vivo
evidence. Nat Rev Drug Discov 2006, 5:493-506.
28. Brakenhielm E, Cao R, Cao Y: Suppression of angiogenesis, tumour
growth, and wound healing by resveratrol, a natural compound in red
wine and grapes. FASEB J 2001, 15:1798-1800.
29. El-Mowafy AM, El-Mesery ME, Salem HA, Al-Gayyar MM, Darweish MM:
Prominent chemopreventive and chemoenhancing effects for
resveratrol: unraveling molecular targets and the role of C-reactive
protein. Chemotherapy 2010, 56:60-65.
30. Kundu JK, Surh YJ: Cancer chemopreventive and therapeutic potential of
resveratrol: mechanistic perspectives. Cancer Lett 2008, 269:243-261.
31. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY,
Heimberger AB, Suki D, Prados M, et al: Prognostic associations of
activated mitogen-activated protein kinase and Akt pathways in
glioblastoma. Clin Cancer Res 2006, 12:3935-3941.
Zhang et al. BMC Cancer 2010, 10:593
http://www.biomedcentral.com/1471-2407/10/593
Page 8 of 932. Miloso M, Bertelli A, Nicolini G, Tredici G: Resveratrol-induced activation of
the mitogen-activated protein kinases, ERK1 and ERK2, in human
neuroblastoma SH-SY5Y cells. Neurosci Lett 1999, 264:141-144.
33. El-Mowafy AM, Alkhalaf M, Nassar NN: Resveratrol reverses ET-1-evoked
mitogenic effects in human coronary arterial cells by activating the
kinase-G to inhibit ERK-enzymes. Int J Cardiol 2009, 136:263-269.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/593/prepub
doi:10.1186/1471-2407-10-593
Cite this article as: Zhang et al.: Resveratrol represses YKL-40 expression
in human glioma U87 cells. BMC Cancer 2010 10:593.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. BMC Cancer 2010, 10:593
http://www.biomedcentral.com/1471-2407/10/593
Page 9 of 9